Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceJoints & skin

Cetyl Myristoleate

A waxy fatty acid ester marketed for arthritis since the 1990s on the strength of a handful of small, industry-linked trials that have never been independently replicated. The story is appealing; the evidence base has barely grown in twenty years.

What the science says

  • Improves knee range of motion and function in osteoarthritis Limited evidence

    The main oral trial (Hesslink 2002, n=64, 68 days) reported a 10.1 degree gain in knee flexion with a cetylated fatty acid complex versus 1.1 degrees on placebo, and a 5.4-point drop on the Lequesne index versus 2.1. Impressive on paper, but this was a single small study funded by the ingredient's commercial developer, with no independent replication in the two decades since.

  • Topical cetylated fatty acid cream improves mobility Limited evidence

    Kraemer 2004 randomised 40 knee OA patients to a cetylated fatty acid cream or placebo cream and found faster stair-climbing and timed up-and-go at 30 minutes and 30 days. The trial shared authors and funding with the oral study, used performance tasks rather than validated pain scales, and lasted only a month.

  • Works as an immune 'reset' that cures arthritis Limited evidence

    This claim traces to 1970s mouse work suggesting cetyl myristoleate protected rodents from adjuvant-induced arthritis. Nothing in the human literature supports disease modification, and the 2006 Ameye systematic review of nutraceuticals in osteoarthritis placed cetyl myristoleate among the compounds with insufficient evidence to recommend.

  • Better than glucosamine or NSAIDs Limited evidence

    No trial has ever compared cetyl myristoleate head-to-head against glucosamine, chondroitin, an NSAID or paracetamol. Marketing comparisons are extrapolations from separate small studies with different endpoints and cannot support a ranking.

Dosage & safety

Studied doseOral products typically supply 350-1,500 mg/day of a cetylated fatty acid complex (often branded Celadrin), taken as divided doses for 4-10 weeks; the 2002 trial used a proprietary complex daily for 68 days. Topical creams are applied twice daily to the affected joint. Many capsules are underdosed relative to the trial products and label the ester amount rather than the complex.
SafetyGenerally well tolerated in the short trials that exist, with mild GI upset the main complaint; no long-term safety data beyond about 10 weeks. It is a fatty acid ester, so people with fat-malabsorption conditions may notice loose stools. Not studied in pregnancy, breastfeeding or children. It is not banned in sport, but the bigger risk is opportunity cost: relying on it can delay exercise therapy, weight management and proven analgesia for a progressive joint disease.

Scientific references

Where to buy

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Joints & skin